Adicet bio presents clinical biomarker data for off-the-shelf car t cell therapy in an oral session at the american college of rheumatology (acr) convergence 2024

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta t cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the adi-001 phase 1 glean trial which demonstrates robust tissue homing, significant car t cell activation, and complete cd19+ b cell depletion in secondary lymphoid tissue will be featured in an oral session at acr convergen.
ACET Ratings Summary
ACET Quant Ranking